Morgan Stanley Maintains Underweight on Genmab, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has maintained an Underweight rating on Genmab (NASDAQ:GMAB) and kept the price target at $32.
March 26, 2024 | 3:03 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley maintains an Underweight rating on Genmab with a $32 price target.
The reaffirmation of an Underweight rating by a major financial institution like Morgan Stanley, along with a maintained price target, suggests a bearish outlook on the stock. This could influence investor sentiment negatively in the short term, potentially leading to a decrease in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100